



August 13, 2016

To
National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

To
BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400051,
Maharashtra, India

Sub: Press release

**Ref: HealthCare Global Enterprises Limited ("the Company") (NSE Scrip Code: HCG/
BSE Scrip Code: 539787)**

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company, at their meeting held on August 12, 2016, *inter alia*, has approved the Financial Results (Limited Review), Standalone and Consolidated for the quarter ended June 30, 2016.

In this respect, we enclose herewith the communication being released to the Press on the Financial Results (Limited Review) for the quarter ended June 2016.

Request you to take this on record.

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer

Encl: as above

HealthCare Global Enterprises Ltd. reports Q1 FY17 results

Revenue growth of 18.2 % (y-o-y)

EBITDA growth of 25.4% (y-o-y)

PAT of INR 50 mn

Bengaluru, August 12, 2016: Healthcare Global Enterprises Limited (“HCG”) today announced its financial results for the quarter ended June 30, 2016 (“Q1 FY17”).

Highlights for the quarter ended June 30, 2016 (Q1 FY17)

- Consolidated Income from Operations (“Revenue”) was **INR 1,676 mn** as compared to **INR 1,417 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **18.2%**.
- Consolidated Profit Before Other Income, Depreciation and Amortisation, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was **INR 236 mn** as compared to **INR 188 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **25.4%**.
- Profit before Taxes and Minority Interest (“PBT”) was **INR 79 million** as compared to a **profit of INR 2.8 mn** in the corresponding quarter of the previous year.
- Profit after Taxes and Minority Interest (“PAT”) was **INR 50 million** as compared to a **loss of INR 5 mn** in the corresponding quarter of the previous year.
- EBITDA excluding losses from new centres was **INR 263 mn**, reflecting a margin of **16.6%** and a growth of **31.2 %** over the corresponding quarter of the previous year.

INR million except per share data

Period Ended June 30	Q1-FY17	Q1-FY16	Growth (y-o-y)
Revenue	1,675.5	1,417.4	18.2%
EBITDA⁽¹⁾	236.3	188.4	25.4%
<i>EBITDA Margin (%)</i>	<i>14.1%</i>	<i>13.3%</i>	
PBT⁽²⁾	78.8	2.8	NM
<i>PBT Margin (%)</i>	<i>4.7%</i>	<i>0.2%</i>	
PAT⁽³⁾	49.8	(5.0)	NM
<i>PAT Margin (%)</i>	<i>3.0%</i>	<i>-0.4%</i>	
Earnings Per Share	0.58	(0.07)	NM

(1) Profit before other income, depreciation and amortization, finance costs, exceptional items and taxes

(2) Profit / (Loss) before tax

(3) Profit / (Loss) for the period

Business Updates for Q1 FY17

- Two new advanced comprehensive cancer centres at Vadodara and Visakhapatnam successfully commenced operations, expanding the HCG network to 19 comprehensive cancer centres and adding 148 beds.
- Adoption of new technologies, including the daVinci robotic surgery system at Bengaluru and Ahmedabad, the TomoTherapy radiotherapy system at Bengaluru and the True Beam radiotherapy systems at Cuttack, Visakhapatnam and Vadodara driving increases in average realizations and margin
- Successful clinical and operational results from Milann's first new centre outside Bengaluru in New Delhi, launched in Q4 FY 16

Commenting on the results, **Dr. B.S. Ajaikumar, Chairman, HealthCare Global Enterprises Ltd.** said, *"We are pleased to report strong operating results in the first quarter of FY 2017. We continue to strengthen our leadership in cancer care, both in terms of commercialization of new technology and the successful expansion of our pan-India network. We are also pleased to report strong performance of the Milann centres and in particular excellent response to our new centre in Delhi. Overall we see good growth prospects in our business across the board. With 8 new cancer centres in development we continue to make great progress towards our mission to make high quality cancer care accessible to all."*

Q1 FY17 Earnings Call

The company will conduct a one hour conference call at **6:00 PM IST on Tuesday, August 16, 2016** where the management will discuss insights about the company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is **+91 22 3960 0627/+91 22 6746 5838**. Other numbers are listed in the conference call invite which is uploaded on the stock exchange and posted on our website.

About HCG Enterprises Ltd.:

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 19 comprehensive cancer centres across India, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centres provide expertise and advanced technologies required for the effective diagnosis and treatment of cancer under one roof. HCG has pioneered the introduction and adoption of several technologies in the country including stereotactic radiosurgery, robotic radiosurgery and the use of genomics for personalized treatment of cancer. Under the "Milann" brand, HCG operates six fertility centres. **For further information**, visit www.hcgel.com or **contact: Company Secretary and Compliance Officer: Sunu Manuel, investors@hcgoncology.com**

Disclaimer: daVinci, Tomotherapy and True Beam are registered trademarks of respective third parties and not of the Company.